Drugs Made In America Acquisition Corp.

(NASDAQ) DMAA

Current Price$10.61

Market Cap$257.82M

Since IPO (2025)+7%

5 YearN/A

1 Year+4%

1 Month+0%

Drugs Made In America Acquisition Corp. Financials at a Glance

Market Cap

$257.82M

Revenue (TTM)

$0.00

Net Income (TTM)

$6.66M

EPS (TTM)

$0.20

P/E Ratio

53.58

Dividend

$0.00

Beta (Volatility)

-0.12 (Low)

Dividend

$0.00

Beta (Volatility)

-0.12 (Low)

Price

$10.61

Volume

432

Open

$10.62

Price

$10.61

Volume

432

Open

$10.62

Previous Close

$10.62

Daily Range

$10.62 - $10.62

52-Week Range

$10.17 - $10.62

Estimated Earnings Date

May 20, 2025

Dividend

$0.00

Beta (Volatility)

-0.12 (Low)

Price

$10.61

Volume

432

Open

$10.62

Previous Close

$10.62

Daily Range

$10.62 - $10.62

52-Week Range

$10.17 - $10.62

Estimated Earnings Date

May 20, 2025

DMAA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Drugs Made In America Acquisition Corp.

Industry

Capital Markets

Sector

Financials

Employees

CEO

Roger Emile Bendelac, MBA

Website

www.dmaacorp.com

Headquarters

Fort Lauderdale, FL 33301, US

DMAA Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

Return on Capital

-1%

Return on Assets

Earnings Yield

1.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$257.82M

Shares Outstanding

24.28M

Volume

432

Avg. Volume

106.66K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$2.82M

EBITDA

-$2.82M

Operating Cash Flow

-$539.19K

Capital Expenditure

$0.00

Free Cash Flow

-$539.19K

Cash & ST Invst.

$6.14K

Total Debt

$0.00

Drugs Made In America Acquisition Corp. Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$257.82M

N/A

Market Cap/Employee

$128.91M

N/A

Employees

N/A

Net Income

$1.97M

+57.1%

EBITDA

-$143.30K

+56.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$14.89K

+1512.9%

Total Debt

$100.00K

+64.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$100.00K

+64.2%

Return on Assets

2.75%

N/A

Return on Invested Capital

-1.09%

N/A

Free Cash Flow

-$91.25K

+63.7%

Operating Cash Flow

-$91.25K

+63.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

LOKVLive Oak Acquisition Corp. V Class A Ordinary Shares

LOKVLive Oak Acquisition Corp. V Class A Ordinary Shares$9.47-4.44%

RTACRenatus Tactical Acquisition Corp I Class A Ordinary Shares

RTACRenatus Tactical Acquisition Corp I Class A Ordinary Shares$10.42+0.00%

SIMASIM Acquisition Corp. I

SIMASIM Acquisition Corp. I$10.88-0.09%

OYSEOyster Enterprises II Acquisition Corp

OYSEOyster Enterprises II Acquisition Corp$10.28+0.00%

TACHTitan Acquisition Corp.

TACHTitan Acquisition Corp.$10.41+0.00%

TACOUBerto Acquisition Corp. Unit

TACOUBerto Acquisition Corp. Unit$10.95+1.58%

TACOBerto Acquisition Corp.

TACOBerto Acquisition Corp.$10.39+0.10%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$201.80+0.05%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.71+0.02%

NOKNokia

NOKNokia$13.98-0.06%

SOFISoFi Technologies

SOFISoFi Technologies$17.71+0.03%

SNAPSnap

SNAPSnap$5.16-0.10%

RXTRackspace Technology

RXTRackspace Technology$6.21+0.05%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$79.93-0.06%

Questions About DMAA

What is the current price of Drugs Made In America Acquisition Corp.?

Drugs Made In America Acquisition Corp. is trading at $10.62 per share.

What is the 52-week range for Drugs Made In America Acquisition Corp.?

Over the past 52 weeks, Drugs Made In America Acquisition Corp. has traded between $10.17 and $10.62.

How much debt does Drugs Made In America Acquisition Corp. have?

As of the most recent reporting period, Drugs Made In America Acquisition Corp. reported total debt of $100.00K.

How much cash does Drugs Made In America Acquisition Corp. have on hand?

Drugs Made In America Acquisition Corp. reported $14.89K in cash and cash equivalents in its most recent financial results.

What is Drugs Made In America Acquisition Corp.’s dividend yield?

Drugs Made In America Acquisition Corp. does not currently have a dividend yield.

Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. Financials at a Glance

DMAA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Drugs Made In America Acquisition Corp.

DMAA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Drugs Made In America Acquisition Corp. Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About DMAA

What is the current price of Drugs Made In America Acquisition Corp.?

What is the 52-week range for Drugs Made In America Acquisition Corp.?

How much debt does Drugs Made In America Acquisition Corp. have?

How much cash does Drugs Made In America Acquisition Corp. have on hand?

What is Drugs Made In America Acquisition Corp.’s dividend yield?

Premium Investing Services